Alector achieves target enrollment in INFRONT-3 Phase 3 trial of latozinemab

Alector (ALEC) has achieved target enrollment in INFRONT-3, the pivotal Phase 3 clinical trial of latozinemab. INFRONT-3 is evaluating the safety and efficacy of latozinemab in slowing disease progression in individuals with frontotemporal dementia due to a progranulin gene mutation. Latozinemab is an investigational human monoclonal antibody designed to block sortilin, a degradation receptor for progranulin. It is intended to elevate PGRN levels and enhance the activity of microglia, the primary cells of the brain’s innate immune system. Latozinemab is the most advanced PGRN modulating product candidate in clinical trials and the most advanced potential treatment for FTD-GRN. Latozinemab is being developed in collaboration with GSK (GSK). Earlier this year, Alector and GSK held a Type C meeting with the U.S. Food and Drug Administration and received scientific advice from the European Medicines Agency regarding INFRONT-3. The companies aligned with the FDA and EMA to conduct the primary analysis on symptomatic FTD-GRN participants, supporting an enrollment target of approximately 90-100 symptomatic participants in INFRONT-3. Alector and GSK achieved target enrollment in INFRONT-3 with 101 symptomatic participants.